1. Weber WC, Streblow DN, Coffey LL. Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure. BioDrugs. 2024; 38(6):727–42. https://doi.org/10.1007/s40259-024-00677-y
2. Robert B, Brown EB. Summary Basis for Regulatory Action. 2004;(1):1–14.
3. de Lima STS, de Souza WM, Cavalcante JW, da Silva Candido D, Fumagalli MJ, Carrera JP, et al. Fatal Outcome of Chikungunya Virus Infection in Brazil. Clin Infect Dis. 2021; 73(7):E2436–43.
4. Constant LEC, Rajsfus BF, Carneiro PH, Sisnande T, Mohana-Borges R, Allonso D. Overview on Chikungunya Virus Infection: From Epidemiology to State-of-the-Art Experimental Models. Front Microbiol. 2021; 12(October):1–20.
5. Amaral JK, Taylor PC, Schoen RT. Bone erosions and joint damage caused by chikungunya virus: a systematic review. Rev Soc Bras Med Trop. 2024; 57(September 2023):1–5.
6. Khongwichit S, Chansaenroj J, Chirathaworn C, Poovorawan Y. Chikungunya virus infection: molecular biology, clinical characteristics, and epidemiology in Asian countries. J Biomed Sci. 2021; 28(1):1–17. https://doi.org/10.1186/s12929-021-00778-8
7. Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adults ≥65 Years of Age. medRxiv. 2024; 2024.10.10.24315205. http://medrxiv.org/content/early/2024/12/13/2024.10.10.24315205.abstract
8. Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4.
9. Gache H, et al. Positive immunogenicity and safety profile for a virus-like particle (VLP) based Chikungunya virus (CHIKV) vaccine: results from a pivotal Phase III trial. https://escmid.reg.key4events.com/AbstractList.aspx?e=21&preview=1&aig=-1&ai=19663
Facebook 
Masuk dengan Email
